Hirschel-Scholz S, Caverzasio J, Bonjour J P
J Clin Invest. 1985 Nov;76(5):1851-6. doi: 10.1172/JCI112178.
Hypocalcemia has been observed in patients receiving WR-2721 [S-,2-(3-aminopropylamino)-, ethylphosphorothioic acid]. WR-2721 is a compound that, after being dephosphorylated, provides protection of normal tissues against radio- and chemotherapy. The hypocalcemic response was accompanied by a decrease in the plasma level of parathyroid hormone (PTH) and by hypomagnesemia. Our present studies in rats on the mechanism of the hypocalcemic effect of WR-2721 indicate that: (a) The phosphorylated and dephosphorylated form of WR-2721 induced an equal dose-dependent decrement in plasma calcium. (b) In intact rats a maximal hypocalcemic dose of WR-2721 reduced urinary cyclic AMP excretion from 70.5 +/- 6.3 to 38.2 +/- 3.1 pmol/ml glomerular filtration rate (GFR), a level comparable to that observed (35.9 +/- 5.2 pmol/ml GFR) in thyroparathyroidectomized (TPTX) rats. (c) WR-2721 given to TPTX rats did not significantly interfere with the calcemic effect of bovine PTH 1-34 infused at 2.5 IU/h. Likewise, the drug did not impair the PTH actions on the renal Ca and inorganic phosphate (Pi) handling, and on the urine cyclic AMP excretion. (d) In TPTX rats made normocalcemic by low Pi diet, the hypocalcemic effect of WR-2721 was only about 25% of that observed in intact animals. However, it was associated with increased urine Ca per milliliter GFR, indicating a PTH-independent inhibitory effect on tubular Ca reabsorption. (e) In WR-2721-treated intact rats, prevention of hypomagnesemia by infusing magnesium chloride did not reduce hypocalcemia. In conclusion, the hypocalcemic effect of WR-2721 is not dependent upon the presence of a phosphate group in the molecule and is not causally related to hypomagnesemia. WR-2721 appears to be a unique hypocalcemic pharmacologic agent with strong inhibitory activity on PTH secretion and additional PTH-independent action on renal Ca reabsorption.
在接受WR-2721[S-,2-(3-氨丙基氨基)-乙基硫代磷酸]治疗的患者中观察到了低钙血症。WR-2721是一种化合物,脱磷酸化后可保护正常组织免受放疗和化疗的影响。低钙血症反应伴随着甲状旁腺激素(PTH)血浆水平的降低和低镁血症。我们目前在大鼠身上对WR-2721低钙血症作用机制的研究表明:(a)WR-2721的磷酸化和脱磷酸化形式均能引起血浆钙同等程度的剂量依赖性降低。(b)在完整大鼠中,WR-2721的最大低钙血症剂量可使尿中环磷酸腺苷(cAMP)排泄量从70.5±6.3降至38.2±3.1 pmol/ml肾小球滤过率(GFR),这一水平与甲状腺甲状旁腺切除(TPTX)大鼠中观察到的水平(35.9±5.2 pmol/ml GFR)相当。(c)给TPTX大鼠注射WR-2721并不会显著干扰以2.5 IU/h输注的牛PTH 1-34的血钙作用。同样,该药物也不会损害PTH对肾脏钙和无机磷酸盐(Pi)处理以及尿cAMP排泄的作用。(d)在通过低磷饮食使血钙正常的TPTX大鼠中,WR-2721的低钙血症作用仅约为完整动物中观察到的作用的25%。然而,这与每毫升GFR尿钙增加有关,表明对肾小管钙重吸收有不依赖PTH的抑制作用。(e)在接受WR-2721治疗的完整大鼠中,通过输注氯化镁预防低镁血症并不能减轻低钙血症。总之,WR-2721的低钙血症作用不依赖于分子中磷酸基团的存在,也与低镁血症没有因果关系。WR-2721似乎是一种独特的低钙血症药理剂,对PTH分泌具有强烈的抑制活性,并对肾脏钙重吸收具有额外的不依赖PTH的作用。